Reviva Pharmaceuticals Holdings (RVPH) EBITDA (2018 - 2026)
Reviva Pharmaceuticals Holdings (RVPH) posted EBITDA of -$3.3 million for Q1 2026, up 8.07% sequentially from -$3.6 million in Q4 2025, and up 49.96% YoY from -$2.2 million in Q1 2025.
Reviva Pharmaceuticals Holdings (RVPH) EBITDA (2018 - 2026) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported EBITDA for 9 years, with the latest figure at -$3.3 million in Q1 2026.
- Quarterly EBITDA rose 49.96% year-over-year to -$3.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16.9 million (up 42.43% YoY) and the FY2025 annual result came in at -$20.2 million, up 34.41% from the prior year.
- EBITDA advanced to -$3.3 million in Q1 2026 per RVPH's latest filing, from -$3.6 million in the prior quarter.
- Over five years, EBITDA peaked at -$3.3 million in Q1 2026 and troughed at -$11.6 million in Q3 2023.
- A 5-year average of -$7.1 million and a median of -$7.0 million in 2023 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2025: EBITDA plunged 297.95% in 2022, then soared 52.38% in 2025.
- Over 5 years, EBITDA stood at -$8.9 million in 2022, then decreased by 8.17% to -$9.6 million in 2023, then surged by 34.67% to -$6.3 million in 2024, then jumped by 43.37% to -$3.6 million in 2025, then grew by 8.07% to -$3.3 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$3.3 million, -$3.6 million, and -$4.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Reviva Pharmaceuticals Holdings | 6.47 Mn | 6.47 Mn | - | -2.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.62 Mn |
| Mar 31, 2026 | -3.27 Mn |
| Dec 31, 2025 | -3.56 Mn |
| Sep 30, 2025 | -4.03 Mn |
| Jun 30, 2025 | -6.07 Mn |
| Mar 31, 2025 | -6.54 Mn |
| Dec 31, 2024 | -6.28 Mn |
| Sep 30, 2024 | -8.46 Mn |
| Jun 30, 2024 | -8.13 Mn |
| Mar 31, 2024 | -7.92 Mn |
| Dec 31, 2023 | -9.62 Mn |
| Sep 30, 2023 | -11.56 Mn |
| Jun 30, 2023 | -11.34 Mn |
| Mar 31, 2023 | -6.98 Mn |
| Dec 31, 2022 | -8.89 Mn |
| Sep 30, 2022 | -5.50 Mn |
| Jun 30, 2022 | -5.52 Mn |
| Mar 31, 2022 | -7.45 Mn |
| Dec 13, 2021 | -3.96 Mn |
| Sep 30, 2021 | -2.48 Mn |